Èlia Prades-Sagarra (Èlia Prades, Elia Prades-Sagarra)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Lymph Node Metastasis

Radiation Induced

Top Venues

Communications biology

This page only lists publications with an associated author ORCID identifier.

Publications

Èlia Prades-Sagarra, Ala Yaromina, Ludwig J Dubois
Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer. Cancers 15 (9) (2023)
Èlia Prades-Sagarra, Ala Yaromina, Ludwig J Dubois
Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer. Cancers 15 (9) (2023)
Marta Fontcuberta-PiSunyer, Ainhoa García-Alamán, Èlia Prades-Sagarra, Noèlia Téllez, Hugo Alves-Figueiredo, Mireia Ramos-Rodríguez, Carlos Enrich, Rebeca Fernandez-Ruiz, Sara Cervantes, Laura Clua, Javier Ramon-Azcon, Christophe Broca, Anne Wojtusciszyn, Nuria Montserrat, Lorenzo Pasquali, Anna Novials, Joan-Marc Servitja, Josep Vidal, Ramon Gomis, Rosa Gasa
Direct reprogramming of human fibroblasts into insulin-producing cells using transcription factors. Communications biology 6 (1) (2023)
Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W Wilmink, Remco J Molenaar, Johannes Crezee, Cornelis J F van Noorden
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1 -Mutated Cancer Cells. Cancers 14 (24) (2022)
Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W Wilmink, Remco J Molenaar, Johannes Crezee, Cornelis J F van Noorden
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1 -Mutated Cancer Cells. Cancers 14 (24) (2022)
Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W Wilmink, Remco J Molenaar, Johannes Crezee, Cornelis J F van Noorden
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1 -Mutated Cancer Cells. Cancers 14 (24) (2022)